Reference
Bayle A, et al. Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact? European Journal of Cancer 113: 28-31, 6 Apr 2019. Available from: URL: http://doi.org/10.1016/j.ejca.2019.02.016
Rights and permissions
About this article
Cite this article
Costly switch to fixed-dose nivolumab, pembrolizumab. PharmacoEcon Outcomes News 826, 7 (2019). https://doi.org/10.1007/s40274-019-5809-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5809-6